A late-stage drug development company specific in oncology and endocrinology.

AEZS-108 happens to be in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe. Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris mentioned, ‘We are very pleased with AEZS-108 gaining orphan-drug designation for ovarian malignancy from the FDA as it would offer it with extra marketplace exclusivity protection. We anticipate reporting the final outcomes from our ongoing European Phase 2 research in ovarian and endometrial tumor, later this year.’..Goldmann, M.D.1 Infections due to these bacterias are preceded by colonization of mucous membranes usually, skin, wounds, or the gastrointestinal system. Colonization occurs through indirect patient-to-patient transmission of MRSA and VRE through the hands of health care suppliers and through contaminated fomites and environmental areas2,3 or, less generally, by direct transmitting from colonized health care providers.4 Standard interventions to prevent the transmission of MRSA and VRE in health care facilities include hands hygiene, the usage of barrier precautions in the treatment of colonized and contaminated patients, the use of dedicated equipment and instruments for these sufferers, and the keeping colonized or infected sufferers in single rooms or multibed areas or areas reserved for such patients.7-18 We hypothesized that culture-based dynamic surveillance for MRSA and VRE and the expanded usage of barrier precautions, in comparison with existing practice, would decrease the incidence of colonization or infection with MRSA or VRE in adult intensive treatment units .